Estimating the global burden of scabies: what else do we need?*

Cox, Victoria; Fuller, L.C.; Engelman, Daniel; Steer, Andrew C.; Hay, Roderick J.

doi:10.1111/bjd.19170

Cited by 33 publications

(25 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The prevalence was generally much lower in developed countries, with very few estimates exceeding 2–4%. 30 Although Australia is considered a developed country with access to universal healthcare, remote indigenous communities continue to experience a very high burden of scabies, affecting 7 out of 10 children before their first birthday. 31 This is more than six times the rate seen in the rest of the developed world.…”

Section: Epidemiologymentioning

confidence: 99%

“…Following secondary GAS skin infections, at-risk minority populations can experience complications, including APSGN and ARF, which are associated with chronic renal impairment and chronic rheumatic heart disease, respectively, and are typically seen in disadvantaged tropical populations, including First Nations Peoples of Australia and New Zealand as well as Pacific Islander communities. 30 , 44 , 45 Emerging evidence is suggestive that GAS impetigo plays a role in ARF when previously GAS pharyngitis was presumed to be the only source of upstream infection. 42 , 46 …”

Section: Complications Of Scabiesmentioning

confidence: 99%

See 1 more Smart Citation

Paediatrics: how to manage scabies

Thompson¹,

Westbury²,

Slape³

2021

DIC

View full text Add to dashboard Cite

This narrative review addresses scabies, a highly contagious, pruritic infestation of the skin caused by the mite S arcoptes scabiei var hominis . Scabies is a common disorder that has a prevalence worldwide estimated to be between 200 and 300 million cases per year. Infestation is of greatest concern in children, the elderly, immunocompromised people and resource-poor endemic populations at risk of chronic complications. A diagnosis of scabies involves a clinical suspicion, a detailed targeted history, clinical examination and contact tracing. Dermoscopy and microscopy, where available, is confirmatory. Due to its infectivity and transmissibility, the management for scabies requires a multimodal approach: topical antiscabetic agents are the first line for most cases of childhood classic scabies and their contacts, which must also be identified and treated to prevent treatment failure and reacquisition. Environmental strategies to control fomite-related reinfestation are also recommended. Oral ivermectin, where available, is reserved for use in high-risk cases in children or in mass drug administration programmes in endemic communities. The prevention of downstream complications of scabies includes surveillance, early identification and prompt treatment for secondary bacterial infections, often superficial but can be serious and invasive with associated chronic morbidity and mortality. Post-scabetic itch and psychosocial stigma are typical sequelae of the scabies mite infestation. The early identification of patients with scabies and treatment of their contacts reduces community transmission. Although time consuming and labour intensive for caregivers, the implementation of appropriate treatment strategies usually results in prompt cure for the child and their contacts. Here, we provide a summary of treatments and recommendations for the management of paediatric scabies.

show abstract

Section: Epidemiologymentioning

confidence: 99%

Section: Complications Of Scabiesmentioning

confidence: 99%

Paediatrics: how to manage scabies

Thompson¹,

Westbury²,

Slape³

2021

DIC

View full text Add to dashboard Cite

show abstract

“…Al igual que en la pediculosis, los datos epidemiológicos de calidad de esta enfermedad son limitados, por lo que la incidencia global puede estar subestimada 25 . Es una de las 15 enfermedades incluidas en el estudio Global burden of disease, en el que se estimó una prevalencia mundial de 175,406,000 casos.…”

Section: Epidemiologíaunclassified

Pediculosis y escabiosis: revisión de la literatura

Ortiz-Flores¹,

Rodríguez-Estavillo²,

Arellano-Mendoza³

et al. 2022

MCUT

View full text Add to dashboard Cite

La pediculosis y la escabiasis son dos de las infestaciones por ectoparásitos más comunes y, debido a su potencial curable, ambas están consideradas por la Organización Mundial de la Salud dentro de las enfermedades tropicales desatendidas. Son vectores de enfermedades graves y se consideran problemas de salud pública en diversos países del mundo. Presentan cuadros clínicos variados y su diagnóstico es esencialmente clínico, por lo que el estudio de las manifestaciones es clave para el control de estas epidemias. Existen diversas opciones terapéuticas y su adecuada indicación llevará al correcto manejo de los pacientes infestados y, por lo tanto, a la disminución de las tasas de contagio.

show abstract

“…Scabies is one of the most common dermatological conditions [ 1 – 3 ] and is estimated to affect over 130 million people globally at any time [ 2 , 4 , 5 ]. It is caused by the Sarcoptes scabiei mite [ 6 ] and is commonly transmitted through direct person-to-person body contact [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

Health care cost of crusted scabies in Aboriginal communities in the Northern Territory, Australia

et al. 2022

View full text Add to dashboard Cite

Background Crusted scabies is a debilitating dermatological condition. Although still relatively rare in the urban areas of Australia, rates of crusted scabies in remote Aboriginal communities in the Northern Territory (NT) are reported to be among the highest in the world. Objective To estimate the health system costs associated with diagnosing, treating and managing crusted scabies. Methods A disease pathway model was developed to identify the major phases of managing crusted scabies. In recognition of the higher resource use required to treat more severe cases, the pathway differentiates between crusted scabies severity grades. The disease pathway model was populated with data from a clinical audit of 42 crusted scabies patients diagnosed in the Top-End of Australia’s Northern Territory between July 1, 2016 and May 1, 2018. These data were combined with standard Australian unit costs to calculate the expected costs per patient over a 12-month period, as well as the overall population cost for treating crusted scabies. Findings The expected health care cost per patient diagnosed with crusted scabies is $35,418 Australian dollars (AUD) (95% CI: $27,000 to $43,800), resulting in an overall cost of $1,558,392AUD (95% CI: $1,188,000 to $1,927,200) for managing all patients diagnosed in the Northern Territory in a given year (2018). By far, the biggest component of the health care costs falls on the hospital system. Discussion This is the first cost-of-illness analysis for treating crusted scabies. Such analysis will be of value to policy makers and researchers by informing future evaluations of crusted scabies prevention programs and resource allocation decisions. Further research is needed on the wider costs of crusted scabies including non-financial impacts such as the loss in quality of life as well as the burden of care and loss of well-being for patients, families and communities.

show abstract

Estimating the global burden of scabies: what else do we need?*

Cited by 33 publications

References 53 publications

Paediatrics: how to manage scabies

Paediatrics: how to manage scabies

Pediculosis y escabiosis: revisión de la literatura

Health care cost of crusted scabies in Aboriginal communities in the Northern Territory, Australia

Contact Info

Product

Resources

About